Telomerase activity and telomere length in patients with acute promyelocytic leukemia: Indicative of proliferative activity, disease progression, and overall survival

Annals of Oncology

Volumn 19, Issue 11, 2008, Pages 1927-1934

  Ghaffari, S H ^a   Shayan Asl, N ^a   Jamialahmadi, A H ^a   Alimoghaddam, K ^a   Ghavamzadeh, A ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Acute promyelocytic leukemia; Arsenic trioxide; NB4; Telomerase activity; Telomere length

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ARSENIC TRIOXIDE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; RETINOIC ACID RECEPTOR ALPHA; TELOMERASE;

ADOLESCENT; ADULT; ARTICLE; CANCER GROWTH; CHROMOSOME ANALYSIS; CHROMOSOME SIZE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME ANALYSIS; FEMALE; HUMAN; HUMAN CELL; LEUKEMIA RELAPSE; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROMYELOCYTIC LEUKEMIA; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT; SOUTHERN BLOTTING; TELOMERE;

EID: 54949099664     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn394     Document Type: Article

References (30)

1. Hahn WC. Role of telomeres and telomerase in the pathogenesis of human cancer. J Clin Oncol 2003; 21: 2034-2043.
2. Djojosubroto MW, Choi YS, Lee HW et al. Telomeres and telomerase in aging, regeneration and cancer. Mol Cells 2003; 15: 164-175.
3. Bryan TM, Englezou A, Dalla PL et al. Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines. Nat Med 1997; 3: 1271-1274.
4. Harley CB, Villeponteau B. Telomere and telomerase in aging and cancer. Curr Opin Genet Dev 1995; 5: 249-255.
5. Tallman MS, Andersen JW, Schiffer CA et al. All-trans retinoic acid in acute promyelocytic leukemia: Long-term outcome and prognostic factor analysis from the North American Intergroup protocol. Blood 2002; 100: 4298-4302.
6. Shen ZX, Chen GQ, Ni JH et al. Use of arsenic trioxide (As203) in the treatment of acutepromyelocytic leukemia (APL). II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997; 89: 3354-3360.
7. Ghavamzadeh A, Alimoghaddam K, Ghaffari SH et al. Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy. Ann Oncol 2006; 171: 131-134.
8. Burnett AK, Grimwade D, Solomon E et al. Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with alltrans retinoic acid: Result of the randomized MRC trial. Blood 1999; 93: 4131-4143.
9. Ghaffari SH, Rostami S, Bashash D et al. Real-time PCR analysis of PML-RARa in newly diagnosed acute promyelocytic leukaemia patients treated with arsenic trioxide as a front-line therapy. Ann Oncol 2006; 17: 1553-1559.
10. Dahse R, Fiedler W, Ernst G. Telomeres and telomerase: Biological and clinical importance. Clin Chem 1997; 43: 708-714.
11. Engelhardt M, Albanell J, Drullinsky P et al. Relative contribution of normal and neoplastic cells determines telomerase activity and telomere length in primary cancers of the prostate, colon, and sarcoma. Clin Cancer Res 1997; 3: 1849-1857.
12. Engelhardt M, Drullinsky P, Gulllem J, Moore MAS. Telomerase and telomere length in the development and progression of premalignant lesions to colorectal cancer. Clin Cancer Res 1997; 3: 1931-1941.
13. Albanell J, Lonardo F, Rusch V et al. High telomerase activity in primary lung cancers: Association with increased cell proliferation rates and advanced pathologic stage. J Natl Cancer Inst 1997; 89: 1609-1615.
14. Gerder R, Roenberg R, Stricker D. Telomere length and human telomerase reverse transcriptase expression as markers for progression and prognosis of colorectal carcinoma. J Clin Oncol 2004; 22: 1807-1814.
15. Kammori M, Takubo K, Nakamura K et al. Telomerase activity and telomere length in benign and malignant human thyroid tissues. Cancer Lett 2000; 175-181.
16. Wu X, Amos CI, Zhu Y et al. Telomere dysfunction: A potential cancer predisposition factor. J Natl Cancer Inst 2003; 95: 1211-1218.
17. Ohyashiki JH, Sashida G, Tauchi T, Ohyashiki K. Telomeres and telomerase in hematologic neoplasia. Oncogene 2002; 21: 680-687.
18. Engelhardt M, MacKenzie K, Drullinsky P et al. Telomerase activity and telomere length in acute and chronic leukemia, pre and post-ex vivo culture. Cancer Res 2000; 60: 610-617.
19. Zhang W, Piatyszek MA, Kobayashi T et al. Telomerase activity in human acute myelogenous leukemia: Inhibition of telomerase activity by differentiation-inducing agents. Clin Cancer Res 1996; 2: 799-803.
20. Xu D, Gruber A, Peterson C, Pisa P. Telomerase activity and the expression of telomerase components in acute myelogenous leukaemia. Br J Haematol 1998; 102: 1367-1375.
21. Huh HJ, Huh JW, Yoo ES et al. hTERT mRNA levels by real-time RT-PCR in acute myelogenous leukemia. Am J Hematol 2005; 79: 267-273.
22. Dikmen ZG, Gellert GC, Jackson S et al. In vivo inhibition of lung cancer by GRN163L: A novel human telomerase inhibitor. Cancer Res 2005; 65: 7866-7873.
23. Wu KD, Orme LM, Shaughnessy J et al. Telomerase and telomere length in multiple myeloma: Correlations with disease heterogeneity, cytogenetic status, and overall survival. Blood 2003; 101: 4982-4989.
24. Hiyama E, Hiyama K, Yokoyama T et al. Correlating telomerase activity levels with human neuroblastoma outcomes. Nat Med 1995a; 1: 249-257.
25. Langford LA, Piatyszek MA, Xu R et al. Telomerase activity in ordinary meningiomas predicts poor outcome. Hum Pathol 1997; 28: 416-420.
26. Remes K, Norrback KF, Rosenquist R et al. Telomere length and telomerase activity in malignant lymphomas at diagnosis and relapse. Br J Cancer 2000; 82: 601-607.
27. Bechter OE, Eisterer W, Pall G et al. Telomere length and telomerase activity predict survival in patients with 8 cell chronic lymphocytic leukemia. Cancer Res 1998; 58: 4918-4922.
28. Ladetto M, Compagno M, Ricca I et al. Telomere length correlates with histopathogenesis according to the germinal center in mature B-cell lymphoproliferative disorders. Blood 2004; 103: 4644-4649.
29. Kolquist KA, Ellisen LW, Counter CM et al. Expression of TERT in early premalignant lesions and a subset of cells in normal tissues. Nat Genet 1998; 19: 182-186.
30. Chou WC, Hawkins AL, Barrett JF et al. Arsenic inhibition of telomerase transcription leads to genetic instability. J Clin Invest 2001; 108: 1541-1547.